Join
Live feed
·
PRReleasevia Quantisnow
ZyVersa Therapeutics Inc. logo

ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes

ByQuantisnow·Wall Street's wire, on your screen.
ZVSA· ZyVersa Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ZVSA (ZyVersa Therapeutics Inc.) and more on Quantisnow.